Literature DB >> 3567519

Predictive power of progesterone receptor status in early breast carcinoma.

R Sutton, M Campbell, T Cooke, R Nicholson, K Griffiths, I Taylor.   

Abstract

Progesterone receptor status (PgR) and oestrogen receptor status (ER) were examined in 332 women with stage I-II breast carcinoma treated at a single centre either by simple mastectomy with (n = 283) or without (n = 6) axillary clearance, or by segmental mastectomy with (n = 18) or without (n = 25) axillary clearance and radiotherapy; median follow-up time was 40 (range 10-60) months. Neither the concentration nor the presence of PgR related to either disease-free interval or survival. However both the presence and the concentration of ER were found to be associated with a longer disease-free interval amongst patients with stage II tumours (P less than 0.01). From this study it appears that progesterone receptor status does not predict outcome in early breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3567519     DOI: 10.1002/bjs.1800740325

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  The prognostic value of tumor-associated carbohydrate structures correlated with gene amplifications in human breast carcinomas.

Authors:  T Fukutomi; S Hirohashi; H Tsuda; T Nanasawa; H Yamamoto; M Itabashi; Y Shimosato
Journal:  Jpn J Surg       Date:  1991-09

2.  Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.

Authors:  R I Nicholson; R A McClelland; J M Gee; D L Manning; P Cannon; J F Robertson; I O Ellis; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

3.  Prognostic value of continuous variables in breast cancer and head and neck cancer. Dependence on the cut-off level.

Authors:  A Courdi; M Héry; P Chauvel; J Gioanni; M Namer; F Demard
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.